Brain Electrode Recording and Heat Treatment for Drug-Resistant Epilepsy
Tests electrode brain mapping and heat-based treatment in people with drug-resistant epilepsy.
Plain-language title generated from the registry record
Registry title: Clinical Trial of SEEG for Drug-resistant Epilepsy
Key facts
- Where
- Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Ürümqi, and Wuhan, ChinaSee the 17 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 70 years old?
Source: NCT07923058, who can take part
Where in China
- Beijing ChaoYang HospitalBeijing, ChinaNo longer taking part
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
- Chinese PLA General HospitalBeijing, ChinaNo longer taking part
- Peking University First HospitalBeijing, ChinaNo longer taking part
- Xuanwu HospitalBeijing, ChinaNo longer taking part
- Xiangya Hospital of Central South UniversityChangsha, ChinaNo longer taking part
- Second Affiliated Hospital of Army Medical UniversityChongqing, ChinaNo longer taking part
- The Second Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaNo longer taking part
- First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNo longer taking part
- Guangzhou Women and Children's medical centerGuangzhou, ChinaNo longer taking part
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaNo longer taking part
- Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhou, ChinaNo longer taking part
- The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
- Qilu Hospital of Shandong UniversityJinan, ChinaNo longer taking part
- The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaNo longer taking part
- Central Theater Command General Hospital of Chinese People's Liberation ArmyWuhan, ChinaNo longer taking part
- Tongji Hospital Affiliated to Tongji Medical College of HUSTWuhan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Pins Medical Co., Ltd
- Trial code
- NCT07923058
- Record updated
- 6 November 2026
- Original description
This trial evaluates the safety and efficacy of SEEG recording and functional mapping for patients with drug-resistant epilepsy. It also assesses the safety and therapeutic effectiveness of SEEG-guided radiofrequency ablation for this patient group. The study will collect clinical evidence to support the standardized application of this combined diagnostic and treatment workflow for drug-resistant epilepsy.Read full original descriptionShow less
A Clinical Trial Evaluating the Safety and Efficacy of Stereoelectroencephalography (SEEG) Electrode Combined With Radiofrequency Lesion System for the Treatment of Drug-Resistant Epilepsy
This trial evaluates the safety and efficacy of SEEG recording and functional mapping for patients with drug-resistant epilepsy. It also assesses the safety and therapeutic effectiveness of SEEG-guided radiofrequency ablation for this patient group. The study will collect clinical evidence to support the standardized application of this combined diagnostic and treatment workflow for drug-resistant epilepsy.
Inclusion: Age ≥ 2 years old and ≤ 70 years old, of any sex; Prior confirmed diagnosis of drug-resistant epilepsy (DRE); Mean epilepsy seizure frequency ≥ 1 episode per month in the 3 months preceding screening; Patients scheduled to undergo stereoelectroencephalography (SEEG) recording and RF thermocoagulation (RF-TC); The subject or their legal representative is capable of understanding the trial purpose, demonstrates sufficient adherence to the study protocol, and has provided signed informed consent.
Exclusion: Subjects who have participated in any other investigational drug or medical device clinical trial within 3 months preceding screening; Patients with known hypersensitivity to any electrode material; Subjects with severe cardiac, hepatic, or renal impairment who, in the investigator's judgment, are unsuitable for participation in this clinical investigation; Any other condition that, in the investigator's opinion, would render the subject unsuitable for participation; Patients with contraindications to MRI; Patients with coagulation dysfunction or known coagulopathy; Women who are pregnant, planning pregnancy within 6 months, or breastfeeding; Patients with contraindications to neurosurgical procedures; Subjects who, in the investigator's judgment, demonstrate poor compliance or are unable to complete the study as required.